RU2503459C2 - Agent for extreme performance stimulation, method for preparing and using it - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns an agent for extreme performance stimulation in the form of a mixture of peptides of molecular weight 2000-5000 Da and peptides of molecular weight 500-900 Da prepared of the infant cattle and/or swine brain in ratio of the ingredients 2/1-3/1, in the concentration of the mixture of peptides in the agent of 5.0-10.0 mg/ml of the aqueous solution or 5.0-10.0 mg/g in the witepsol suppository; a method for preparing the above agent for extreme performance stimulation; using the above agent for parenteral administration or for rectal administration.

EFFECT: group of inventions provides higher performance efficiency and tolerance in trained individuals at least by 20% as compared with the reference group.

3 cl, 5 ex, 4 dwg, 11 tbl

Description

The invention relates to medicine and relates to medical devices for a specific effect on body functions.

Known technical solutions made at the level of inventions, which increase the performance and endurance of persons subject to intense physical exertion. [1-3]

The indicated technical solutions are a food product [1] enriched in phospholipids or protein-amino acid food products [2] or protein-peptide modules for food production [3] for nutrition of athletes or other persons leading an active lifestyle.

It is characteristic that the above foods or food additives, firstly, do not significantly increase working capacity and endurance, and only after prolonged (2-3 months or more) consumption of these products, and, secondly, increasing health and stamina occurs mainly due to an increase in muscle mass and, thirdly, these foods are not stimulants of performance and endurance as such, i.e. do not meet the necessary requirements for work in extreme conditions.

In the available scientific, technical and patent literature, no analogues and prototype are found that meet the proposed stimulator for working in extreme conditions.

The technical result, the achievement of which the creation of this invention is aimed, is to increase the working capacity and endurance when working in extreme conditions (extreme and transcendental and prolonged physical exertion, stressful situations, etc.), for example, during special operations and similar critical events requiring maintaining high performance especially in conditions of extreme psycho-emotional stress. Also the technical result, the achievement of which the creation of this invention is directed, is to obtain a highly active agent for stimulating work in extreme conditions.

The technical result is achieved by the fact that the claimed tool for stimulating work in extreme conditions is a mixture of peptides with a molecular weight of 2000-5000 Da, obtained from the ventral and dorsal hippocampus (hippocampus) of the sulcus (sulcus cinguli) amygdala complex (nucleus amygdalae) of the limbic system and from the caudate nucleus (nucleus caudatus) and the hypothalamus (hypothalamus) (A) and peptides with a molecular weight of 500-900 Da obtained from the central gray matter surrounding the sylvian aqueduct (aquaeductus cerebri Sylvii) of the midbrain ( mesencephalon) (B) the brain of cattle and / or pigs under the age of one year with a mass ratio of components A and B from 2/1 to 3/1, and the concentration of the mixture of peptides in the tool is 5.0-10.0 mg / ml in an aqueous solution or 5.0-10.0 mg / g in a suppository based on vitepsol.

The technical result is also achieved by the fact that the method of obtaining funds for stimulating work in extreme conditions involves grinding the frozen parts of the ventral and dorsal hippocampus (hippocampus) of the waist sulcus (sulcus cinguli) of the amygdala complex (nucleus amygdalae) of the limbic system of the brain, and the caudate nucleus (nucleus caudatus ) and hypothalamus (hypothalamus) (A) of the brain of cattle or pigs not older than 1 year old, homogenization in water, hydrolysis in the presence of acetic acid and zinc chloride, extraction of hydrolysis zat, separation of the extract from ballast substances by separation through materials with a retention capacity of 10,000 Da, precipitation of the hydrolyzate with a 30% solution of acetic acid, washing the precipitate with acetone, dissolving the precipitate in water and separating the 2000-5000 Da fraction by preparative chromatography, dissolving it in water and drying by lyophilization; however, the process also includes simultaneous separation of the midbrain, namely

the central gray matter surrounding the sylvian aqueduct (aquaeductus cerebri Sylvii) (B), freezing, hydrolyzing and separating the extract from the ballast substances by separation through materials with a retention capacity of more than 2000 Da and sedimentation of the fraction up to 2000 Da with 30% acetic acid solution, washing the precipitate with acetone, dissolving the precipitate in water and isolating the 500-900 Da fraction from the dissolved extract by supercritical fluid extraction at a critical CO2 temperature of 31.1 ° C and a critical pressure of 7.3 ± 0.1 atm., dissolving the 500-900 Da fraction in water and drying lyophilization and further preparation of the product by mixing aqueous solutions of fractions of 2000-5000 Da (A) and 500-700 Da (B) with a mass ratio of 2/1 to 3/1 and a concentration of 5.0-10.0 mg / ml in aqueous solution or by introducing the mixture into vitepsol to a content of 5.0-10.0 mg / g and then forming suppositories.

As a raw material for the production of peptides, parts of the brain departments of slaughtered cattle and / or pigs (cattle) no older than 1 year old are used, namely, the ventral and dorsal hippocampus (hippocampus) of the lumbar groove (sulcus cinguli) of the amygdala complex (nucleus amygdalae) limbic brain system, as well as the caudate nucleus (nucleus caudatus) and the hypothalamus (hypothalamus), and the midbrain (mesencephalon), namely: the central gray matter surrounding the sylvian aqueduct (aquaeductus cerebri Sylvii).

The hydrolysis of the crushed parts of the brain is carried out either in an acidic medium (acetic acid + zinc chloride) or in the presence of proteolytic enzymes - serine proteases, fungal serine endoprotease, pepsin, pectofostidine (P10X), etc.

The separation of the active components of the agent during hydrolysis and separation of the hydrolyzate is carried out by ultrafiltration and preparative chromatography, as well as supercritical fluid extraction.

The proposed tool for stimulating work in extreme conditions is an aqueous solution of a mixture of (A) peptides with a molecular weight of 2000-5000 Da obtained by preparative chromatography of purified and filtered hydrolyzate of parts of the brain parts of slaughtered cattle and / or pigs (cattle) older than 1 year, namely: ventral and dorsal hippocampus (hippocampus) of the cingulate sulcus (sulcus cinguli), amygdala complex (nucleus amygdalae) of the limbic system of the brain, as well as the caudate nucleus (nucleus caudatus) and hypothalamus ca (hypothalamus) and (B) - peptides with a molecular weight of 500-900 Da, obtained from a purified and filtered hydrolyzate of the central gray matter surrounding the sylvian aqueduct (aquaeductus cerebri Sylvii) of the midbrain (mesencephalon), and the mass ratio of peptides to molecular weighing 2000-5000 Da (A) and 500-900 Da (B) in the product is from 2/1 to 3/1, respectively, and the concentration of the mixture in the solution is 5.0-10.0 mg / ml or 5.0-10 , 0 mg / g in suppositories based on Vitepsol.

It should be noted that the claimed tool consists of two active components, each of which also (as will be shown below on examples of specific applications of the claimed tool) has a stimulating effect on work in extreme conditions, however, when used together, a synergistic effect is manifested - with an equal weight used means, a mixture of two components is twice as effective as each component separately.

It should also be noted that the mass ratio of components A and B beyond the stated limits in the direction of decreasing or increasing leads either to a decrease in the stimulating effect, or practically does not change it. The same can be said about a single dose of the proposed drug (10-30 mg, depending on the age of the recipient)

Another significant feature of the claimed tool is that it can be detected in the blood of the recipient by analytical means only during the first 15-25 minutes. after parenteral administration (and with rectal administration, it cannot be detected at all by modern analytical means). This circumstance is crucial in the practice of stimulating athletes.

Get a tool to stimulate work in extreme conditions as follows.

In slaughtered animals (10-month-old calves and 8-month-old pigs), the brain is removed, parts of the ventral and dorsal hippocampus of the cingulate sulcus of the amygdala complex of the limbic system of the brain, the caudate nucleus and hypothalamus (A), as well as the central gray matter of the midbrain surrounding the sylvia water supply (B). The indicated parts of the brain A and B are individually frozen at least to -40 ° C [6] and then ground and homogenized in water, homogenate A is hydrolyzed at 20 ° C in the presence of acetic acid and zinc chloride, extracted, the extract is separated off from ballast substances by separation through materials with a retention capacity of 10,000 Da, the hydrolyzate is precipitated with a 30% acetic acid solution, the precipitate is washed with acetone, the precipitate is dissolved in water and 2000-5000 Da fractions are separated by preparative chromatography (LC-30 Nexera chromatograph, LC-8A pump, the inner diameter of the column is 20 mm), the fraction 2000-5000 Da is separated, it is dissolved in water and dried by lyophilization (yield 1.35 g / 100 g of raw material), and the homogenate of part B of the brain is hydrolyzed at 20 ° C in the presence of pepsin, then the hydrolyzate is extracted, the extract is separated from the ballast substances by separation through materials with a retention capacity of more than 2000 Da, the purified extract is separated by fluid extraction at a critical temperature of СО _{2 of} 31.1 ° C and a critical pressure of 7.3 ± 0.1 atm, and a fraction of 500 is separated -900 Yes, dissolve it in water and dry the lyoph ilization (yield 1.07 g / 100 g of raw material); then prepare the tool by mixing solutions of fractions of 2000-5000 Da (A) and 500-700 Da (B) with a mass ratio of 2/1 to 3/1 and a concentration of 5.0-10.0 mg / ml in an aqueous solution or by introducing the mixture into vitepsol to a content of 5.0-10.0 mg / g and then forming suppositories.

The study of the impact of the claimed funds on improving adaptogenic activity, performance and endurance of humans (and animals) in a state of high physical and psycho-emotional stress is carried out in accordance with GOST R 15.105-2001, according to standard operating procedures of laboratories and according to the "Rules of laboratory practice in the Russian Federation "(Order of the Ministry of Health of the Russian Federation No. 267 of 06/19/2003), as well as the national standard of the Russian Federation" Principles of Good Laboratory Practice tics ”GOST R 53434-2009. To study the properties of the claimed funds, the following compositions were prepared (see Table 1)

Table 1 Composition No. Component A content (% wt) Component B content (% wt) Note one 67 33 2 75 25 3 one hundred - four - one hundred 5 80 twenty 6 55 45

Example 1

Determination of changes in physical performance of outbred white rats under aerobic power loads.

The influence of the claimed means on physical performance is determined by measuring the duration of the run on the treadmill from the start of the run until the animal develops a state of final refusal to perform physical activity. The duration of one test cycle is 27 days.

The test is carried out as follows. Preliminary training of animals at the stand (treadmill, 1 day, 10 min at an angle of inclination of the treadmill tape 20 ° and its speed 23 m / min), administration of the agent to animals (within 21 days), observation of animals after the termination of administration of the agent (7 days) . A repeated test cycle with the introduction of funds is carried out

Form 4 groups of laboratory rats of 12 animals each. The first group receives the claimed agent (composition 1. Table 1), the second - peptides A, (composition 3, Table 1), the third - peptides B (composition 4, Table 1) and the fourth (control) - physiological saline. Drugs are administered rectally.

Doses of administration: A - 0.5 mg / goal., B - 0.30 mg / goal., A + B - 0.25 + 0.15, i.e. 0.40 mg / goal.

40 minutes after the introduction of the product - run 15 minutes at a speed of 27 m / min and with a tape inclination of 20 °. The voltage is 40 V. The indicators are taken on the 1st, 8th, 15th, 21st and 27th day of the experiment. The main indicator is the total contact time of the rat with the electric platform and the running time.

The endurance of rats when running on a treadmill is presented in Table 2.

table 2 Means A + B 1st day 8th day 15th day 21st day 27th day . running (sec) 253 ± 22 260 ± 21 273 ± 26 267 ± 25 249 ± 19 Peptides A . running (sec) 243 ± 22 254 ± 20 228 ± 23 225 ± 19 207 ± 15 Peptides B . running (sec) 254 ± 25 258 ± 18 259 ± 28 229 ± 15 206 ± 11 The control . running (sec) 241 ± 26 203 ± 23 168 ± 21 133 ± 13 143 ± 13

As can be seen from Table 2, the endurance of rats compared with the control group increases significantly. It should be noted the manifestation of a synergistic effect when using a mixture of peptides A and B.

Table 3 presents the endurance of rats under the action of various types of the claimed funds (in composition and dosage)

Table 3 Composition 5 (Table 1) 1st day 8th day 15th day 21st day 27th day . running (sec) 254 ± 25 258 ± 18 259 ± 28 229 ± 15 206 ± 11 Composition 6 (Table 1) . running (sec) 243 ± 26 218 ± 23 173 ± 20 163 ± 13 155 ± 14 Composition 2 (Table 1), a dose of 0.80 mg / goal. . running (sec) 252 ± 23 256 ± 19 247 ± 23 225 ± 15 204 ± 15 Composition 2 (Table 1), dose 0.20 mg / goal. . running (sec) 241 ± 26 203 ± 23 168 ± 21 163 ± 13 155 ± 17

Figure 1 (see page 10 of the description) presents the effect of the claimed funds on the endurance of experimental animals from the original (100%). Areas of 20 days represent the use of the claimed drug, 30 days - a break in the application. The test time (days) is plotted on the abscissa axis and the change in endurance as a percentage of the original value is plotted on the ordinate axis. Figure 2 (see page 10 of the description) presents the effect of the claimed funds on the endurance of experimental animals in contact with an electrical stimulating platform treadmill. Test time (days) is plotted on the abscissa axis and contact duration is plotted on the ordinate axis. Lines 1, 2, 3 and 4 show the effect of the claimed drug (A + B), peptides A and peptides B individually and data for the control group, respectively.

Example 2

To identify the pharmacological activity of the claimed drug, a test of "despair" or forced swimming, which reflects the state of depression of animals. The forced swimming test is a combined hard form of stress that combines physical and emotional components.

In the experiment, animals of all groups are subjected to stress - swimming in a pool with a load. Water temperature + 24 ° С.

The test results are presented in Table 4

Table 4 Means (A + B) 1st day 8th day 15th day 22nd day 27th day First swim 78.3 ± 4.1 201.3 ± 5.8 257.8 ± 7.2 336.8 ± 8.0 325.5 ± 10 Repeated 57.3 ± 2.4 149.3 ± 3.7 196.2 ± 9.4 285.6 ± 9.7 290.8 ± 10.3 Third 62.2 ± 3.2 174.9 ± 5.0 238.6 ± 7.0 311.5 ± 10.0 308.5 ± 10.8 Peptides A First swim 84.3 ± 3.9 193.4 ± 4.8 214.3 ± 4.4 227.25 ± 4.5 209.7 ± 6.7 Repeated 64.9 ± 3.9 143.3 ± 3.5 145.2 ± 3.4 159.0 ± 4.28 146.5 ± 4.42 Third 72.7 ± 3.4 160.4 ± 3.0 165.0 ± 3.3 204.6 ± 10.9 175.3 ± 3.0 Peptides B The first 79.7 ± 5.4 125.5 ± 6.2 178.0 ± 6.4 218.0 ± 6.6 197.8 ± 4.7 Repeated 58.2 ± 4.2 91.9 ± 5.3 144.0 ± 7.6 187.3 ± 5.4 162.0 ± 3.3 Third 66.8 ± 4.3 101.3 ± 5.5 147.8 ± 3.8 181.6 ± 6.7 176.3 ± 4.2 The control First swim 63.8 ± 3.3 66.8 ± 2.6 71.0 ± 3.2 71.9 ± 3.9 91.4 ± 3.3 Repeated 49.3 ± 3.5 46.4 ± 2.4 52.7 ± 2.7 54.5 ± 3.0 68.7 ± 3.2 Third 53.9 ± 2.7 54.7 ± 2.2 62.3 ± 3.0 62.3 ± 3.4 79.8 ± 2.9

Example 3

Hypoxia test.

A measure of the sensitivity of animals to acute hypobaric hypoxia is the life expectancy at the "height". Each animal is "raised" to a critical height (11.5 thousand m) at a speed of 165 m / s, where it was located to an agonal state. Designations:

Runway - the time of the first fall (transition to a lying position), characterizing the threshold of the body's reaction to this effect.

VZh - life time at "height" (before the appearance of agonal breathing).

GDP - the time of posture recovery after the animal “descends” from the “height”

KEZ - coefficient of effectiveness of protection (life time in the experiment / life time in the control) The results of tests of acute hypobaric hypoxia are presented in Table 5

Table 5 Indicator 1 day 8 day 15 day 22 day 27 day Means (A + B) Runway, sec 7.9 ± 1.1 12.5 ± 0.9 20 ± 1.4 38.3 ± 2.2 33.7 ± 1.3 VZh, sec 87.5 ± 5.6 184.6 ± 12.4 273.3 ± 18.3 363.3 ± 16.1 354.2 ± 9.7 GDP. sec 24.6 ± 2.6 21.3 ± 1.9 16.3 ± 1.6 8.8 ± 1.1 10.4 ± 1.0 Peptides A Runway, sec 7.9 ± 0.7 7.9 ± 0.7 10.4 ± 0.9 15.8 ± 1.0 13.8 ± 1.1 VZh, sec 95.8 ± 7.3 123.3 ± 7.9 239.6 ± 12.0 285.8 ± 9.0 262.1 ± 10.7 GDP, sec 25.4 ± 2.3 22.9 ± 1.7 20.8 ± 1.7 15 ± 1.7 16.3 ± 1.8 Peptides B Runway, sec 10 ± 1,1 10.8 ± 1.0 9.2 ± 1.0 9.2 ± 1.2 10.4 ± 0.9 VZh, sec 104.2 ± 6.2 113.8 ± 5.4 128.8 ± 6.4 191.3 ± 5.9 186.3 ± 6.5 GDP, sec 24.6 ± 2.3 22.1 ± 2.1 17.9 ± 1.9 16.3 ± 1.5 17.1 ± 0.9 The control Runway, sec 7.92 ± 0.74 8.75 ± 0.65 7.5 ± 0.75 8.75 ± 0.65 10 ± 0.62 VZh, sec 105.8 ± 6.2 92.9 ± 5.5 95.8 ± 3.7 107.1 ± 6.3 97.1 ± 5.1 GDP, sec 24.2 ± 2.6 21.3 ± 1.5 23.3 ± 2.3 25.8 ± 2.0 25.4 ± 1.9

Protection effectiveness indicators (CEC) * for acute hypobaric hypoxia (to its own background indicators) are presented in Table 6

Table 6 Groups KEZ 8 day 15 day 22 day 27 day Means (A + B) 2.10 3.12 4.15 3.93 Peptides A 1.28 2,50 2.98 2.73 Peptides B 1.25 2.42 2.84 2.63 The control 1.0 1,0 1,0 1,0

Example 4

The impact of the proposed drug on large laboratory animals (mini-pigs) at maximum physical exertion.

4 groups of 6 heads of mini-pigs weighing 18 ± 1.9 kg are formed, males, age 8 months. The first group receives the claimed drug, the second - peptides A, the third - peptides B and the fourth (control) - placebo. Drugs are administered rectally. Doses of administration: A - 0.56 mg / kg, B - 0.28 mg / kg, agent (A + B) - 0.28 + 0.14 mg / kg, Animals are forced to run on a treadmill. (Torneo T-203).

The duration of the run and the distance covered are measured.

The endurance indicators of mini-pigs are presented in Table 7

Table 7 agent (A + B) 1st day 8th day 15th day 21st day 27th day running time (min) 26.1 ± 1.2 32.4 ± 1.4 34.5 ± 1.3 37.9 ± 1.1 37.4 ± 1.3 distance traveled (m) 2600 ± 150 3500 ± 100 3900 ± 120 4700 ± 120 4750 ± 150 peptides A running time (min) 27.0 ± 1.1 28.1 ± 1.0 29.8 ± 0.6 31.6 ± 1.4 31.3 ± 1.2 distance traveled (m) 2500 ± 100 3100 ± 150 3300 ± 100 4100 ± 150 4000 ± 120 peptides B running time (min) 26.0 ± 1.1 28.1 ± 1.0 29.8 ± 0.6 31.0 ± 1.2 31.3 ± 1.4 distance traveled (m) 2600 ± 130 2900 ± 120 3100 ± 100 3300 ± 150 3400 ± 100 control Group duration (min) 26.6 ± 1.2 27.0 ± 1.4 27.9 ± 1.3 28.2 ± 0.9 28.2 ± 1.9 distance traveled (m) 2500 ± 120 2600 ± 150 2700 ± 150 2900 ± 150 2900 ± 150

It should be noted that, along with an increase in endurance, mini-pigs also increased their speed of movement.

Figure 3 (see page 15 of the description) shows the effect of the claimed drug depending on the form of application (curve 1 - rectally, curve 2 - parenteral) and the dose of the drug (mg).

Figure 4 (see page 15 of the description) shows the cyclic effect of the claimed drug with maximum effect (areas bounded by rectangles, dashed lines) indicating the maximum effect in the period from the 21st to the 41st day and then from the 65th to 85th day, etc. with designated intervals with intervals between the maximum effect from the 42nd to the 64th day, from the 86th to the 108th .. etc.

Example 5

The effect of the claimed funds is checked on athletes. Volunteers are selected - cyclists (24 people with close anthropometric data, age 20-22), and swimmers (24 people with close anthropometric data, age 18-20 years). Both cyclists and swimmers are divided into 4 groups of 6 people each. The first group receives the claimed agent (composition 1. Table 1), the second - peptides A, (composition 3, Table 1), the third - peptides B (composition 4, Table 1) and the fourth (control) - physiological saline. Drugs are administered rectally. Doses of administration: A - 20.0 mg, B - 10.0 mg, A + B - 10.0 + 5.0 mg.

The influence of the claimed means on the physical performance of cyclists is determined by measuring the duration of the “races” on a bicycle ergometer (911S) with an adjustable load (20 ° rise) from the start of the “race” until the athlete develops a state of final refusal to perform physical activity.

Table 8 presents the effect of the claimed funds on the physical performance of cyclists at maximum speed (spurt).

Table 8 agent (A + B) 1st day 8th day 15th day 21st day 27th day the duration of the "race" (min) 4,5 ± 0,2 7.1 ± 0.5 7.8 ± 0.3 8.4 ± 0.2 8.2 ± 0.5 peptides A the duration of the "race" (min) 4.6 ± 0.3 5.7 ± 0.2 6.2 ± 0.1 6.8 ± 0.2 6.6 ± 0.3 peptides B the duration of the "race" (min) 4.2 ± 0.1 5.6 ± 0.2 6.1 ± 0.3 6.7 ± 0.1 6.5 ± 0.2 control Group the duration of the "race" (min) 4.3 ± 0.3 4,5 ± 0,1 4.6 ± 0.2 4.6 ± 0.5 4,5 ± 0,1

Table 9 shows the effect of the claimed tool on the physical performance of cyclists at the stayer speed (~ 60% of the maximum speed load).

Table 9 agent (A + B) 1st day 8th day 15th day 21st day 27th day distance traveled (m) 8500 ± 150 11000 ± 100 13000 ± 100 15500 ± 120 14200 ± 100 peptides A distance traveled (m) 7600 ± 100 9800 ± 150 11000 ± 100 12800 ± 150 12300 ± 120 peptides B distance traveled (m) 7200 ± 130 8900 ± 120 10400 ± 120 11600 ± 100 10900 ± 100 control Group distance traveled (m) 6300 ± 120 6500 ± 150 6900 ± 100 7100 ± 100 6900 ± 150

The influence of the claimed means on the overall physical endurance of swimmers (crawl) is determined by measuring the duration of swimming at a speed of 60-62% of the competition from the start of the swim until the athlete develops a state of refusal to perform physical activity.

Table 10 presents the effect of the claimed funds on the overall physical endurance of swimmers.

Table 10 agent (A + B) 1st day 8th day 15th day 21st day 27th day swimming time (min) 25.0 ± 3 30.0 ± 2 34.0 ± 3 38.0 ± 4 37.0 ± 3 peptides A swimming time (min) 24.0 ± 2 27.0 ± 3 31.0 ± 3 34.0 ± 2 33.0 ± 2 peptides B swimming time (min) 25.0 ± 1 27.0 ± 3 31.0 ± 2 35.0 ± 3 34.0 ± 3 control Group swimming time (min) 24.0 ± 2 25.0 ± 3 24.0 ± 2 23.0 ± 5 22.0 ± 4

The influence of the proposed tool on the speed capabilities of swimmers is determined by measuring the distance traveled over 5 minutes of swimming at a speed of presumably ~ 95% of the competition. Table 11 presents the effect of the proposed tool on the speed capabilities of swimmers.

Table 11 agent (A + B) 1st day 8th day 15th day 21st day 27th day Speed (km / h at 95% load) 5.0 ± 0.1 6.2 ± 0.15 6.9 ± 0.1 7.6 ± 0.1 7.5 ± 0.1 peptides A Speed (km / h at 95% load) 4.9 ± 0.1 5.7 ± 0.1 6.3 ± 0.1 6.9 ± 0.1 6.8 ± 0.1 peptides B Speed (km / h at 95% load) 4.85 ± 0.1 5.8 ± 0.1 6.2 ± 0.1 6.7 ± 0.1 6.5 ± 0.1 control Group Speed (km / h at 95% load) 4.9 ± 0.1 5.0 ± 0.1 5.1 ± 0.1 5.0 ± 0.1 4.7 ± 0.1

17

As can be seen from the description, examples of the impact of the claimed drug on performance in extreme conditions (especially when exposed to extreme physical and psycho = emotional stress), as well as from comparison with control examples, the claimed tool stimulates an increase in performance and endurance in trained people by at least 20 % compared to the original,

Sources of information taken into account when preparing the application.

1. RU 2370158 C2, M. cl. A23L 1/30, publ. 2010 year

2. RU 2375923 C2, M. cl. A23L 1/30, publ. 2010 year

3. RU 2388350 C2, M. cl. A23L 1/30, publ. 2010 year

Claims (3)

1. A tool to stimulate work in extreme conditions, characterized in that it is a mixture of peptides with a molecular weight of 2000-5000 Yes, obtained from the ventral and dorsal hippocampus (hippocampus) of the sulcus cinguli of the amygdala complex (nucleus amygdalae) of the limbic system and from the caudate nucleus (nucleus caudatus) and the hypothalamus (hypothalamus) (A) and peptides with a molecular weight of 500-900 Da obtained from the central gray matter surrounding the sylvian aqueduct (aquaeductus cerebri Sylvii) of the midbrain (mesencephalon) (B) of the brain croup cattle and / or pigs under the age of one year with a mass ratio of components A and B from 2/1 to 3/1, and the concentration of the mixture of peptides in a medium of 5.0-10.0 mg / ml in an aqueous solution or 5.0 -10.0 mg / g in suppositories based on Vitepsol. 2. The method of obtaining funds for stimulating work in extreme conditions according to claim 1, characterized in that the brain is removed from slaughtered animals, parts of the ventral and dorsal hippocampus (hippocampus) of the cingulate sulcus (sulcus cinguli) of the amygdala complex (nucleus amygdalae) of the limbic system are excised brain, caudate nucleus (nucleus caudatus) and hypothalamus (hypothalamus) (A), as well as the central gray matter of the midbrain (mesencephalon) surrounding the sylvian aqueduct (aquaeductus cerebri Sylvii) (B), these parts of the brain A and B are frozen separately by exchange at least -40 ° C, then crushed and homogenized in water, homogenate A is hydrolyzed at 20 ° C in the presence of acetic acid and zinc chloride, extracted, the extract is separated from the ballast substances by separation through materials with a retention capacity of 10,000 Da, the hydrolyzate is precipitated 30 % solution of acetic acid, the precipitate is washed with acetone, the precipitate is dissolved in water, 2000-5000 Da fractions are separated by preparative chromatography, dissolved in water and dried by lyophilization, and the homogenate of part B of the brain is hydrolyzed and 20 ° C in the presence of pepsin hydrolyzate further extracted, the extract is separated from the ballast substances by separation through materials with a retention capacity of over 2000 Da, separated purified extract fluid extraction under the critical temperature of CO ₂ 31,1 ° C and critical pressure of 7,3 ± 0 , 1 atm., A fraction of 500-900 Yes is separated, it is dissolved in water and dried by lyophilization, then the obtained fractions are dissolved in water at a concentration of 5.0-10.0 mg / ml and aqueous solutions of fractions are mixed at a mass ratio of 2/1 up to 3/1 or enter a mixture of solutions in viteps l to content 5.0-10.0 mg / g and then forming suppositories. 3. The use of funds to stimulate work in extreme conditions according to claims 1 and 2, in the form of an aqueous solution with a concentration of the active substance of 5.0-10.0 mg / ml for single parenteral administration at a dose of 10-30 mg, or in the form of a suppository based on vitepsol with an active substance content of 5.0-10.0 mg / g for a single rectal administration in a dose of 10-30 mg.

Images